NRT study debated
This article was originally published in The Tan Sheet
Executive Summary
Conclusions that nicotine replacement therapy has not increased smoking cessation rates since it switched OTC "have the potential to damage public confidence in NRT and may deter smokers from using effective treatment," according to a letter in Dec. 25 JAMA. Commenting on a recent study in the journal, Mikael Franzon, PhD, et al., Pharmacia, maintain the trial was "nonrandomized, noncontrolled" and "limited by retrospective self-reporting" of study participants (1"The Tan Sheet" Sept. 16, 2002, p. 11). Lindsay Stead, University of Oxford, et al., echo these assertions, noting it is "premature to draw inferences" from findings derived from self-reported data in a single state (California). In reply, study author John Pierce, PhD, UC-San Diego, says that falsely raising smokers' expectations about NRT without providing an "adequate explanation of the limitations...may be counterproductive in the long-term"...
You may also be interested in...
NRT Outcomes In California Study Counter “Authoritative” Data – GSK
Recently published data indicating nicotine replacement therapy efficacy has diminished over the years with OTC availability is at odds with "authoritative reviews and conclusions" supporting the use of such products, GlaxoSmithKline maintained
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.